GordonMD® Global Investments LP announced today that Amlogenyx Inc. has completed a seed funding round of USD 14 million. Amlogenyx, a subsidiary of Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE), is researching and developing novel gene therapies for Alzheimer’s disease and other amyloid diseases.
“I am pleased to collaborate with Amlogenyx; its promising Alzheimer’s disease therapeutic has yielded exciting results in pursuing a therapy that has the potential to change the outlook for this disease,” said Dr. Craig Gordon, Founder and Chief Investment Officer of GordonMD®.
“Amlogenyx’s first product candidate is a protease that we developed alongside Sandra D’Azzo Ph.D. at St. Jude Children’s Research Hospital in Memphis,” said Emil Kakkis, M.D., Ph.D., CEO of Ultragenyx. “The study found that the enzyme can break up and degrade efficiently Aβ42, the protein many consider responsible for Alzheimer’s debilitating effects.”
The seed round was led by GordonMD® and associated investors, as well as Ultragenyx.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.